Celldex Therapeutics
CLDX
253 hedge funds and large institutions have $3.16B invested in Celldex Therapeutics in 2026 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 106 increasing their positions, 57 reducing their positions, and 21 closing their positions.
133% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 21
86% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 57
37% more capital invested
Capital invested by funds: $2.31B → $3.16B (+$850M)
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
11% more funds holding
Funds holding: 228 → 253 (+25)
0.69% less ownership
Funds ownership: 109.01% → 108.32% (-0.69%)
40% less call options, than puts
Call options by funds: $11.3M | Put options by funds: $18.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$83.9M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$53.5M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$53.3M |
| 4 |
BlackRock
New York
|
+$52.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$35.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$101M |
| 2 |
CC
Commodore Capital
New York
|
-$43.5M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$38.8M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$29.7M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$16.7M |
CLDX Hedge Fund Activity: Q2 2026 in Review
253 institutional investors reported a position in Celldex Therapeutics (CLDX) for Q2 2026, worth a combined $3.16B — up 37% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CLDX positions and 21 closed out — a net gain of 28 holders — while 106 added to existing stakes and 57 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $83.9M. The largest seller was Point72 Asset Management, cutting an estimated $101M.
- 253 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2026, up from 228 in Q1 2026.
- Funds reported $3.16B of Celldex Therapeutics stock for Q2 2026, up 37% quarter-over-quarter.
- 49 funds opened new Celldex Therapeutics positions in Q2 2026 and 21 closed out, a net change of +28 holders.
- The largest Celldex Therapeutics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $83.9M added.
- The largest Celldex Therapeutics seller in Q2 2026 was Point72 Asset Management, an estimated $101M sold.
Based on aggregated 13F filings for Q2 2026.